Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Recruiting Phase 3 Interventional

A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis

ClinicalTrials.gov ID: NCT06016842

Public ClinicalTrials.gov record NCT06016842. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 11, 2026, 5:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase III Randomised, Parallel-Group, Double-Blind, Placebo-Controlled, Two-Arm Study to Evaluate the Efficacy and Safety of Elafibranor 80 mg on Long-Term Clinical Outcomes in Adult Participants With Primary Biliary Cholangitis (PBC)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The participants of this study will have confirmed Primary Biliary Cholangitis (PBC) and cirrhosis (scarring of the liver). PBC is a slowly progressive disease, characterised by damage to the bile ducts in the liver, leading to a build-up of bile acids which causes further damage. The liver damage in PBC may lead to cirrhosis. PBC may also be associated with multiple symptoms. Many patients with PBC may require liver transplant or may die if the disease progresses and a liver transplant is not done. This study will compare a daily dose of elafibranor (the study drug) to a daily dose of placebo (a dummy treatment) and will last up to 3.5 years for each participant. The main aim of this study is to determine if elafibranor is better than placebo in preventing clinical outcome events showing disease worsening (including progression of disease leading to liver transplant or death). This study will also study the safety of long-term treatment with elafibranor, as well as the impact on symptoms such as itching and tiredness.

Study identification

NCT ID
NCT06016842
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
Ipsen
Industry
Enrollment
276 participants

Conditions and interventions

Interventions

Drug · Other

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 30, 2023
Primary completion
May 30, 2029
Completion
May 30, 2029
Last update posted
Aug 30, 2026

2023 – 2029

United States locations

U.S. sites
42
U.S. states
18
U.S. cities
35
Facility City State ZIP Site status
Arizona Liver Health Tucson Arizona 85641 Recruiting
Arkansas Diagnostic Center, PA Little Rock Arkansas 55130 Terminated
Southern California Research Center Coronado California 92118 Recruiting
Cedars-Sinai Medical Center Los Angeles California 90048 Withdrawn
GastroIntestinal BioSciences Los Angeles California 90067 Active, not recruiting
University of California Los Angeles Los Angeles California 90404 Withdrawn
University of California Davis Medical Center Sacramento California 95817 Recruiting
University of Colorado Aurora Colorado 80045 Recruiting
Peak Gastroenterology Associates Colorado Springs Colorado 80829 Recruiting
South Denver Gastroenterology, P.C. Englewood Colorado 80113 Recruiting
Rocky Mountain Gastroenterology Littleton Colorado 80120 Recruiting
University Of Miami School Of Medicine, Center For Liver Diseases Miami Florida 33136 Recruiting
Bolanos Clinical Research Pembroke Pines Florida 12105 Recruiting
International Center for Research Tampa Florida 33614 Recruiting
University of Kansas Medical Center (KUMC) - University of Kansas Liver Center - Hepatology Clinic Kansas City Kansas 66160 Not yet recruiting
Louisiana Research Center, LLC Shreveport Louisiana 71103 Recruiting
University of Michigan Health System Ann Arbor Michigan 48109 Recruiting
Huron Gastroenterology Associates - Center for Digestive Care Ypsilanti Michigan 48197 Withdrawn
Mayo Clinic Rochester Minnesota 55905 Recruiting
Southwest Gastroenterology Associates, PC (SWGA) Albuquerque New Mexico 87109 Terminated
NYU Langone Gastroenterology and Hepatology Associates New York New York 10016 Recruiting
University of Pittsburgh Pittsburgh Pennsylvania 15213 Recruiting
Medical University of South Carolina Charleston South Carolina 29425 Recruiting
Gastroenterology Center of the Midsouth Cordova Tennessee 38138 Recruiting
Texas Clinical Research Institute Arlington Texas 22201 Recruiting
American Research Corporation Austin Texas 78757 Recruiting
Rush University Medical Center - University Cardiovascular Surgeons Dallas Texas 60612 Withdrawn
Liver Center of Texas Dallas Texas 75203 Terminated
Methodist Transplant Physicians Dallas Texas 75203 Recruiting
University of Texas Southwestern Medical Center at Dallas Dallas Texas 75390 Recruiting
Baylor Scott & White All Saints Medical Center - Forth Worth Fort Worth Texas 76104 Withdrawn
Liver Associates of Texas Houston Texas 77030 Recruiting
Houston Methodist Cancer Center Houston Texas 77584 Active, not recruiting
Gastro health & Nutrition Katy Texas 77904 Terminated
American Research Corporation at The Texas Liver Institute San Antonio Texas 78015 Recruiting
Impact Research Tx Waco Texas 76710 Withdrawn
University of Virginia Medical Center Charlottesville Virginia 22903 Recruiting
Bon Secours St. Mary's Hospital of Richmond, Inc Richmond Virginia 23226 Recruiting
Virginia Commonwealth University Medical Center - West Hospital Richmond Virginia 23298 Not yet recruiting
Medstar Georgetown Transplant Institute University Hospital (MGUH) Columbia Washington 20007 Withdrawn
Velocity Clinical Research at Liver Institute Northwest Seattle Washington 98105 Recruiting
University Physicians and Surgeons Inc, dba Marshall Health Huntington West Virginia 25701 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 144 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06016842, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 30, 2026 · Synced Sep 11, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06016842 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →